Publication: Análisis del plegamiento anómalo de HLA-B27 y su papel en la patogenia de la espondilitis anquilosante
Loading...
Official URL
Full text at PDC
Publication Date
2018-08-30
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La Espondilitis Anquilosante (EA) es una enfermedad inflamatoria crónica fuertemente asociada al antígeno leucocitario humano B27 (HLA-B27). Los subtipos de HLA-B27 se asocian de forma diferencial a EA. B*27:02, B*27:04 y B*27:05 se asocian fuertemente, B*27:07 se asocia aunque no siempre y B*27:06 y B*27:09 no se asocian o lo hacen débilmente. Existen varias hipótesis que tratan de explicar el mecanismo que subyace a la asociación de esta molécula con la enfermedad. Este trabajo se basa en la hipótesis del plegamiento anómalo de la molécula de HLA-B27. Esta molécula tiende a plegarse mal y se acumula en el retículo endoplásmico (RE). Esto genera respuestas de estrés que conducen a la liberación de citoquinas proinflamatorias como IL-23 que produce inflamación en las entesis. La vía de degradación asociada al RE (ERAD) debería ser capaz de eliminar las moléculas de B27 mal plegadas del RE. ERAD consiste en el reconocimiento y marcaje de proteínas mal plegadas, su retrotranslocación al citosol, su deglicosilación, ubiquitinación y transporte al proteasoma para su degradación. Nos planteamos analizar en qué paso se interrumpe la vía de ERAD en los subtipos asociados a enfermedad y describir las vías de ERAD que se asocian a B27 mediante la susceptibilidad a la degradación mediada por las proteínas del citomegalovirus humano, US2 y US11, que utilizan la maquinaria de ERAD para eliminar la cadena pesada de los antígenos de clase I del RE. Hemos demostrado que todos los subtipos de HLA-B27, asociados o no a enfermedad, se pliegan, en distinto grado, de forma anómala. B*27:05 y B*27:02 son los subtipos que peor se pliegan y unen mayor cantidad de calnexina en un intento de plegarse correctamente. El subtipo asociado B*27:04 se pliega mejor y une menos calnexina. Las moléculas de HLA-B27 mal plegadas son reconocidas y marcadas por la maquinaria de ERAD (BiP y EDEM1). B*27:02 y B*27:05 unen mayor cantidad de BiP y EDEM1 que B*27:04, indicando que este último se pliega de modo más eficiente. Ninguno de los subtipos de HLA-B27 analizados se unen a OS9, pero si se unen a SEL1L y a la Derlina-1. B*27:02 y B*27:05 unen mayor cantidad de SEL1L y Derlina-1 que B*27:04, indicando de nuevo, que el plegamiento de B*27:04 es más eficiente. OS9 probablemente no participa en la degradación de HLA-B27. Otra proteína no identificada podría ejercer el papel de OS9 y transferir las proteínas mal plegadas a SEL1L que a su vez debería transferirlas a Hrd1. A partir de la Derlina-1, una proteína implicada en la retrotranslocación, los subtipos de HLA-B27 no interaccionan con la maquinaria de ERAD...
Ankylosing Spondylitis (AS) is a chronic inflammatory disease which is strongly associated with the human leukocyte antigen B27 (HLA-B27). HLA-B27 subtypes are differentially associated with AS. B*27:05, B*27:04 and B*27:02 are strongly associated with AS, B*27:07 is associated but not always and B*27: 06 and B*27:09 are not associated. There are several hypotheses trying to explain the mechanism that underlies this association. This work is based on the HLA-B27 misfolding hypothesis. This molecule tends to misfold and as a result of misfolding, it accumulates in the endoplasmic reticulum (ER). This generates stress responses that lead to the release of proinflammatory cytokines such as IL-23 that produces enthesitis. The ER associated degradation pathway (ERAD) should be able to eliminate the misfolded B27 heavy chains from the ER. ERAD encompasses recognition and labelling of misfolded proteins, retrotranslocation to the cytosol, its deglycosylation, ubiquitination and transport to the proteasome for degradation. We aimed to analyse each step of the ERAD pathway, in order to know in which step this pathway is blocked in AS-associated subtypes, and to describe the ERAD pathways that are associated to HLA-B27 in the context of US2 and US11 mediated degradation. The human cytomegalovirus products, US2 and US11 hijack the cellular machinery that operates on endogenous misfolded proteins, the ERAD pathway. They induce a rapid dislocation of newly synthesized class I heavy chains. We have demonstrated that all HLA-B27 subtypes analysed, AS-associated or not, misfold to different degrees. B*27:05 and B*27:02 are the ones with the worst folding phenotype and they bind more calnexin in an attempt to correctly fold. The AS-associated subtype B*27:04 folds better and binds less calnexin. Misfolded HLA-B27 molecules are recognised and labelled by the ERAD components BiP and EDEM1. B*27:02 and B*27:05 bind more BiP and EDEM1 than B*27:04, indicating that the latter folds more efficiently. None of the HLA-B27 subtypes analysed bind to OS9, but they do bind to the later components SEL1L and Derlin-1. B*27:02 and B*27:05 bind more SEL1L and Derlin-1 than B*27:04, again indicating that B*27:04 folding is more efficient. OS9 probably does not participate in HLA-B27 degradation. Another unidentified protein could play the role of OS9 and transfer misfolded proteins to SEL1L which, in turn, should transfer them to Hrd1. From Derlin-1, which is a protein involved in retrotranslocation, the interaction of HLA-B27 subtypes with the ERAD machinery is lost...
Ankylosing Spondylitis (AS) is a chronic inflammatory disease which is strongly associated with the human leukocyte antigen B27 (HLA-B27). HLA-B27 subtypes are differentially associated with AS. B*27:05, B*27:04 and B*27:02 are strongly associated with AS, B*27:07 is associated but not always and B*27: 06 and B*27:09 are not associated. There are several hypotheses trying to explain the mechanism that underlies this association. This work is based on the HLA-B27 misfolding hypothesis. This molecule tends to misfold and as a result of misfolding, it accumulates in the endoplasmic reticulum (ER). This generates stress responses that lead to the release of proinflammatory cytokines such as IL-23 that produces enthesitis. The ER associated degradation pathway (ERAD) should be able to eliminate the misfolded B27 heavy chains from the ER. ERAD encompasses recognition and labelling of misfolded proteins, retrotranslocation to the cytosol, its deglycosylation, ubiquitination and transport to the proteasome for degradation. We aimed to analyse each step of the ERAD pathway, in order to know in which step this pathway is blocked in AS-associated subtypes, and to describe the ERAD pathways that are associated to HLA-B27 in the context of US2 and US11 mediated degradation. The human cytomegalovirus products, US2 and US11 hijack the cellular machinery that operates on endogenous misfolded proteins, the ERAD pathway. They induce a rapid dislocation of newly synthesized class I heavy chains. We have demonstrated that all HLA-B27 subtypes analysed, AS-associated or not, misfold to different degrees. B*27:05 and B*27:02 are the ones with the worst folding phenotype and they bind more calnexin in an attempt to correctly fold. The AS-associated subtype B*27:04 folds better and binds less calnexin. Misfolded HLA-B27 molecules are recognised and labelled by the ERAD components BiP and EDEM1. B*27:02 and B*27:05 bind more BiP and EDEM1 than B*27:04, indicating that the latter folds more efficiently. None of the HLA-B27 subtypes analysed bind to OS9, but they do bind to the later components SEL1L and Derlin-1. B*27:02 and B*27:05 bind more SEL1L and Derlin-1 than B*27:04, again indicating that B*27:04 folding is more efficient. OS9 probably does not participate in HLA-B27 degradation. Another unidentified protein could play the role of OS9 and transfer misfolded proteins to SEL1L which, in turn, should transfer them to Hrd1. From Derlin-1, which is a protein involved in retrotranslocation, the interaction of HLA-B27 subtypes with the ERAD machinery is lost...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Ciencias Químicas, Departamento de Bioquímica y Biología Molecular I, leída el 23-06-2017